Traders Buy Pfizer, Inc. (PFE) on Weakness

Investors purchased shares of Pfizer, Inc. (NYSE:PFE) on weakness during trading hours on Tuesday. $223.53 million flowed into the stock on the tick-up and $113.53 million flowed out of the stock on the tick-down, for a money net flow of $110.00 million into the stock. Of all equities tracked, Pfizer had the 5th highest net in-flow for the day. Pfizer traded down ($0.09) for the day and closed at $35.06

Several equities research analysts have issued reports on the stock. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday. Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research report on Tuesday, October 3rd. Finally, Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $38.32.

The stock’s 50 day moving average price is $35.84 and its 200-day moving average price is $33.91. The stock has a market cap of $208.51 billion, a P/E ratio of 25.65 and a beta of 1.00.

Pfizer (NYSE:PFE) last announced its earnings results on Monday, October 30th. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.03. The firm had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.61 earnings per share. Equities research analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.65%. Pfizer’s payout ratio is currently 94.12%.

In other Pfizer news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock valued at $15,813,961 in the last ninety days. Company insiders own 0.06% of the company’s stock.

A number of institutional investors have recently made changes to their positions in PFE. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer during the second quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer during the second quarter worth approximately $103,000. D. Scott Neal Inc. lifted its holdings in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC acquired a new position in shares of Pfizer during the second quarter worth approximately $120,000. Finally, Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of Pfizer during the first quarter worth approximately $121,000. 69.01% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Traders Buy Pfizer, Inc. (PFE) on Weakness” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/10/31/traders-buy-pfizer-inc-pfe-on-weakness.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit